Esen Tarik, Falay Okan, Tarim Kayhan, Armutlu Ayse, Koseoglu Ersin, Kilic Mert, Seymen Hülya, Sarikaya Ahmet Furkan, Kiremit Murat Can, Balbay Mevlana Derya, Canda Abdullah Erdem, Baydar Dilek Ertoy, Kordan Yakup, Demirkol Mehmet Onur, Tilki Derya
Department of Urology, Koc University Hospital, Istanbul, Turkey.
Department of Nuclear Medicine, Koc University Hospital, Istanbul, Turkey.
Eur Urol Focus. 2021 Mar;7(2):288-293. doi: 10.1016/j.euf.2021.01.004. Epub 2021 Jan 25.
Results from prospective trials have shown higher accuracy of prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) in detection of lymph node metastasis (LNM) compared to conventional imaging.
To evaluate the accuracy of Ga-PSMA-11 PET/CT for LNM detection in patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (PLND).
DESIGN, SETTING, AND PARTICIPANTS: Between June 2014 and November 2020, 96 patients with Ga-PSMA PET/CT for primary staging underwent RP and extended PLND.
The results from Ga-PSMA PET/CT were compared with histologic data from primary PLND in 96 patients. All Ga-PSMA PET/CT scans were centrally reviewed.
Of 96 patients, 15.6% (n = 15) harbored LNMs. The median prostate-specific antigen at Ga-PSMA PET/CT was 8.0 ng/ml (interquartile range 5.5-11.7). The majority of patients had intermediate- (52.1%) or high-risk disease (41.7%). Biopsy grade group 4 and 5 was present in 22.9% and 15.6%, respectively. The Ga-PSMA PET/CT scans identified eight of 15 patients (53.3%) as LN-positive (true positive). The calculated per-patient sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of Ga-PSMA PET/CT in the detection of LNM were 53.3%, 98.8%, 88.9%, 92.0%, and 91.7%, respectively. The per-patient sensitivity and specificity in the detection of LNMs larger than 2 mm were 61.5% and 98.8%, respectively. The main limitation is the retrospective design of the study.
Ga-PSMA PET/CT is accurate in lymph node staging and the results support its use for primary staging of prostate cancer.
We compared prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) findings with histopathology results after extended lymph node dissection and showed that it is accurate in detecting lymph node metastases. Our results support the use of PSMA PET/CT for primary staging of prostate cancer.
前瞻性试验结果表明,与传统成像相比,基于前列腺特异性膜抗原(PSMA)的正电子发射断层扫描(PET)/计算机断层扫描(CT)在检测淋巴结转移(LNM)方面具有更高的准确性。
评估镓-PSMA-11 PET/CT在接受根治性前列腺切除术(RP)和扩大盆腔淋巴结清扫术(PLND)患者中检测LNM的准确性。
设计、地点和参与者:2014年6月至2020年11月期间,96例因初始分期接受镓-PSMA PET/CT检查的患者接受了RP和扩大PLND。
将96例患者的镓-PSMA PET/CT结果与初次PLND的组织学数据进行比较。所有镓-PSMA PET/CT扫描均进行集中审核。
96例患者中,15.6%(n = 15)存在LNM。镓-PSMA PET/CT检查时前列腺特异性抗原的中位数为8.0 ng/ml(四分位间距5.5 - 11.7)。大多数患者患有中级(52.1%)或高危疾病(41.7%)。活检分级组4级和5级分别占22.9%和15.6%。镓-PSMA PET/CT扫描在15例患者中识别出8例(53.3%)为淋巴结阳性(真阳性)。计算得出镓-PSMA PET/CT在检测LNM时的患者个体敏感性、特异性、阳性预测值、阴性预测值和准确性分别为53.3%、98.8%、88.9%、92.0%和91.7%。在检测大于2 mm的LNM时,患者个体敏感性和特异性分别为61.5%和98.8%。主要局限性是本研究的回顾性设计。
镓-PSMA PET/CT在淋巴结分期方面准确,其结果支持将其用于前列腺癌的初始分期检测。
我们将基于前列腺特异性膜抗原(PSMA)的正电子发射断层扫描(PET)/计算机断层扫描(CT)结果与扩大淋巴结清扫术后的组织病理学结果进行了比较,结果表明其在检测淋巴结转移方面准确。我们的结果支持将PSMA PET/CT用于前列腺癌的初始分期检测。